Sanofi's PARP Inhibitor Plus Chemo May Be A Lethal One-Two Punch In Triple-Negative Breast Cancer

News that Sanofi-Aventis' PARP inhibitor iniparib conferred "significant clinical benefit" in a proof of concept study against metastatic triple-negative breast cancer – published online Jan. 5 by the New England Journal of Medicine – has generated excitement about the approach, but a Phase III study powered for statistically meaningful results in overall and progression-free survival will tell the tale.